Olivier Soula

Olivier Soula has a diverse work experience in the biotech and pharmaceutical industry. Olivier co-founded ADOCIA in 2005 and held multiple roles, including Chief Executive Officer and Director of Research & Development. ADOCIA is dedicated to innovative protein formulations for diabetes treatment, and Olivier has co-authored nearly 40 patents in this field. In 2011, they co-founded Glowbl and served as the President. Prior to these ventures, Olivier spent 8 years at Flamel Technologies (now Avadel Pharmaceuticals) as the Director of Nanotechnology. Olivier led the development of Medusa, a technological platform for sustained release of therapeutic proteins, and successfully conducted clinical trials for three projects.

Olivier Soula's education history is as follows:

From 1990 to 1993, Olivier studied at the Ecole Nationale Supérieure de Chimie de Mulhouse, earning a degree in Biotechnology and Chemistry. Following this, from 1992 to 1993, they attended the Université de Haute-Alsace Mulhouse-Colmar and obtained a D.E.A. in Organic Chemistry.

In 1995, Olivier began pursuing a Doctor of Philosophy degree at the Université de Lyon. Olivier specialized in L'École Doctorale Matériaux and concluded their studies in 1997.

Finally, from 2005 to 2007, Olivier attended the iaelyon School of Management and earned a Master of Business Administration (MBA) degree.

These are the sequential educational achievements of Olivier Soula, based on the provided chronological information.